Provided by Tiger Trade Technology Pte. Ltd.

Sanofi SA

46.76
-0.3200-0.68%
Post-market: 46.760.00000.00%17:05 EDT
Volume:2.23M
Turnover:104.76M
Market Cap:112.50B
PE:12.44
High:47.59
Open:47.57
Low:46.64
Close:47.08
52wk High:55.73
52wk Low:43.32
Shares:2.41B
Float Shares:2.20B
Volume Ratio:0.88
T/O Rate:0.10%
Dividend:2.27
Dividend Rate:4.86%
EPS(TTM):3.76
EPS(LYR):3.76
ROE:6.66%
ROA:4.65%
PB:1.34
PE(LYR):12.44

Loading ...

Sanofi Investors Might Have to Wait for Update on Strategy -- Market Talk

Dow Jones
·
Apr 10

Sanofi Could Get Boost From Dupixent U.S. Price -- Market Talk

Dow Jones
·
Apr 10

Sanofi becomes market authorization holder for Nuvaxovid in Canada

TIPRANKS
·
Apr 09

Sanofi Says Lunsekimig Meets Primary, Key Secondary Endpoints in Phase 2 Respiratory Studies

MT Newswires Live
·
Apr 07

Trump Will Impose 100% Tariff on Some Patented Drugs

Tiger Newspress
·
Apr 03

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sanofi (SNY), Milestone Pharmaceuticals (MIST) and Connect Biopharma Holdings (CNTB)

TIPRANKS
·
Mar 31

Sanofi Shares Fall After Company Reports Second Cancer Case in Trial -- Market Talk

Dow Jones
·
Mar 30

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading

MT Newswires Live
·
Mar 27

Sanofi Says Subcutaneous Form of Sarclisa for Multiple Myeloma Wins EU Panel Support

MT Newswires Live
·
Mar 27

AstraZeneca Hits Goal in Lung Disease Where Rivals Missed -- Market Talk

Dow Jones
·
Mar 27

Sanofi SA Stock (SNY) Moved Up by 3.33% on Mar 25: Key Drivers Unveiled

TradingKey
·
Mar 26

Regeneron, Sanofi get approval for Dupixent to treat bullous pemphigoid in Japan

TIPRANKS
·
Mar 24

Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

GlobeNewswire
·
Mar 24

Sanofi Advances Early Autoimmune Antibody Program With New Phase 1 Study Update

TIPRANKS
·
Mar 21

Sanofi SA Stock (SNY) Moved Up by 3.07% on Mar 19: Key Drivers Unveiled

TradingKey
·
Mar 20

European Equities Traded in the US as American Depositary Receipts Fall Sharply in Thursday Trading

MT Newswires Live
·
Mar 19

Sanofi Says US FDA Grants Venglustat Breakthrough Therapy Designation for Type 3 Gaucher Disease

MT Newswires Live
·
Mar 18

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

Dow Jones
·
Mar 11

Teva, Blackstone Life Sciences Enter $400 Million Funding Deal to Advance Duvakitug

MT Newswires Live
·
Mar 04

Sanofi Says Rilzabrutinib Receives Orphan Drug Status in Japan

MT Newswires Live
·
Mar 02